Indoleamine 2,3-Dioxygenase (IDO) Expression Is an Independent Prognostic Marker in Esophageal Adenocarcinoma.

Heike LoeserMax KraemerFlorian GebauerChristiane BrunsWolfgang SchröderThomas ZanderHakan AlakusArnulf HoelscherReinhard BuettnerPhilipp LohneisAlexander Quaas

Published in: Journal of immunology research (2020)

Our study emphasizes the importance of immunomodulation in EAC marking IDO as a potential biomarker. Beyond this, IDO might indicate a subgroup of EAC with an explicit survival benefit.

Keyphrases

poor prognosis
squamous cell carcinoma
randomized controlled trial
binding protein
radiation therapy